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CONCLUSION
Immune-mediated necrotizing (IMNM) is a subgroup of 
idiopathic inflammatory myopathies (IIM), which comprise 
a small percentage of the 5-10 cases/million per year of 
IIM.   Anti-centromere antibody association has not been 
previously reported in the literature.  IMNM is characterized 
by absence of muscle inflammation on biopsy with proximal 
muscle weakness, elevated total creatine kinase level (CK), 
statin use, presence of anti-signal recognition particle 
antibody (SRP) or anti-3-hydroxy-3-methylglutarylcoenzyme 
A reductase antibody positivity, and resistance to conventional 
immunosuppressives.
We present the rare case of a 28 year old female with anti-centromere associated, connective tissue mediated IMNM 
refractory to initial systemic corticosteroids and successfully treated with IVIG.
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CASE DESCRIPTION
A 28 year old African- American female with no significant 
medical history presented to our hospital with debilitating, 
severe proximal muscle weakness of predominately hip flexors, 
dysphagia along with dysarthrophonia over the last 4 months 
with a highly elevated CK (16540 U/L). MRI of the bilateral 
thighs was notable for bilateral multifocal thigh muscular 
edema consistent with myositis.  Left vastus lateralis biopsy 
demonstrated a necrotizing myopathy without inflammatory cell 
infiltrates.  Laboratory studies were notable for negative Jo-1 
Antibody, weakly positive SRP antibodies and a positive anti-
nuclear antibody, present in Anti-Centromere pattern.  
Images 1a and 1b: Coronal and sagittal left thigh MRI images 
demonstrating substantial edema related to the adductor magnus, vastus 
lateralis, distal vastus medialis, biceps femoris, and semimembranosus.
Images 2a and 2b: Coronal and sagittal right thigh MRI 
images demonstrating multifocal edema in the adductor magnus, 
vastus lateralis, vastus intermedius, and rectus femoris as well as 
semimembranosus.
Pathological  Specimen 1a and 1b: Several necrotic (1b) and degenerating myofibers 
are present including scattered fibers undergoing myophagocytosis with mild fibrosis (1a)  and no 
evidence of inflammatory cell infiltrates or vasculitis.  Findings all are consistent with necrotizing 
autoimmune myopathy.
The patient was treated with 1mg/kg solumedrol for 5 days and placed on oral prednisone equivalent.  Due to refractory 
symptoms and known aggressive course of IMNM, she was transitioned to monthly intravenous immunoglobulin (IVIG) 
infusions.  Her symptoms and CK began to drastically improve after her second IVIG infusion. 
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